FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308381568> ?p ?o ?g. }

• W4308381568 abstract "<h3>Background</h3> CCAAT/Enhancer Binding Protein β (C/EBPβ) is a basic leucine zipper (bZIP) transcription factor that causes aberrant gene activation in many cancers. Upregulated or overactivated C/EBPβ drives oncogenesis by promoting tumor survival and proliferation¹ and is a critical regulator of the immunosuppressive environment.² Specifically, C/EBPβ regulates macrophage differentiation, promoting the expression of M2 myeloid-derived suppressor cells (MDSCs) that contribute to suppression of antitumor immunity and correlate with poor prognosis.³ Reprogramming tumor-associated macrophages (TAMs) from M2 to M1 phenotype represents a potential strategy to enhance antitumor immunity. ST101 is a novel peptide antagonist that prevents C/EBPβ dimerization and inhibits C/EBPβ-dependent gene expression. Confirmed responses in melanoma and other tumors prompted evaluation of ST101 impact on macrophage differentiation. <h3>Methods</h3> Primary human macrophages were cultured from peripheral blood mononuclear cells (hPBMCs) and activated toward the M1 or M2 phenotype by LPS and IFNγ (M1) or IL-4 (M2), respectively, in the presence of ST101. Macrophage M1 (CD80, CD86) and M2 (CD163, CD206) expression were analyzed by flow cytometry and rtPCR. Paired biopsy tissue from the ST101 Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors were collected during screening (prior to ST101 exposure) and within 24 hrs of ST101 administration during cycle 2 of therapy. Nanostring gene expression analysis was peformed to determine differential gene expression and the impact of ST101 on the tumor microenvironment. <h3>Results</h3> Treatment with pharmacologically relevant concentrations of ST101 (2.5, 5 or 10 µM) resulted in dose-dependent reduction in M2+ macrophage and corresponding induction of M1+ macrophage. At the highest ST101 concentration, a 12-fold reduction in the M2 to M1 ratio was observed without substantial impact on cell viability. Paired patient biopsy tissue from the ST101 Phase 1-2 clinical study indicates a decrease in C/EBPβ target gene IL-6 signaling, an important driver of the M2 macrophage phenotype. Decreased IL-6 signaling resulted in an increase in the tumor-infiltrating macrophage vs. tumor-infiltrating lymphocyte (TIL) ratio, and a decrease in the regulatory T cell (Treg) vs. TIL ratio in tumor samples of treated patients. <h3>Conclusions</h3> Overall, these results validate the potential of ST101 in reprogramming M2 macrophages to M1, support a novel, macrophage-driven mechanism of action for ST101 as an anticancer agent and support future exploration of ST101 in immune-oncology therapeutic strategies. <h3>Trial Registration</h3> ClinicalTrials. gov Identifier: NCT04478279 <h3>References</h3> Homma J, Yamanaka R, Yajima N, Tsuchiya N, Genkai N, Sano M, Tanaka R. Increased expression of CCAAT/enhancer binding protein ß correlates with prognosis in glioma patients. <i>Oncology Reports</i> 2005;<b>15</b>:595–601. Ruffell D, Mourkioti F, Gambardella A, Kirstetter P, Lopez RG, Rosenthal N, Nerlov C. A CREB-C/EBPß cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. <i>PNAS</i> 2009;<b>106</b>:17475–17480. Marigo I, Bosio E, Solito S, Mesa C, Fenandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPß transcription factor. <i>Immunity</i>. 2010;<b>32</b>:790–802. <h3>Ethics Approval</h3> ST101 study sites all have obtained ethics approval prior to study start. All participants gave consent prior to starting the study. Advarra’s IRB Organization (IORG) Number is 0000635; Columbia University Medical Center Institutional Review Board FWA# 00002636; North East – Newcastle & North Tyneside 1 Research Ethics Committee DUKE UNIVERSITY HEALTH SYSTEM Institutional Review Board for Clinical Investigations." @default.
• W4308381568 created "2022-11-11" @default.
• W4308381568 creator A5002575629 @default.
• W4308381568 creator A5002720443 @default.
• W4308381568 creator A5003770647 @default.
• W4308381568 creator A5019291778 @default.
• W4308381568 creator A5024662956 @default.
• W4308381568 creator A5026438002 @default.
• W4308381568 creator A5048924826 @default.
• W4308381568 creator A5053055306 @default.
• W4308381568 creator A5055944597 @default.
• W4308381568 creator A5068416680 @default.
• W4308381568 creator A5069069870 @default.
• W4308381568 creator A5069777765 @default.
• W4308381568 creator A5071560112 @default.
• W4308381568 creator A5077439508 @default.
• W4308381568 creator A5087754052 @default.
• W4308381568 creator A5087792780 @default.
• W4308381568 date "2022-11-01" @default.
• W4308381568 modified "2023-09-25" @default.
• W4308381568 title "1173 ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses" @default.
• W4308381568 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1173" @default.
• W4308381568 hasPublicationYear "2022" @default.
• W4308381568 type Work @default.
• W4308381568 citedByCount "0" @default.
• W4308381568 crossrefType "proceedings-article" @default.
• W4308381568 hasAuthorship W4308381568A5002575629 @default.
• W4308381568 hasAuthorship W4308381568A5002720443 @default.
• W4308381568 hasAuthorship W4308381568A5003770647 @default.
• W4308381568 hasAuthorship W4308381568A5019291778 @default.
• W4308381568 hasAuthorship W4308381568A5024662956 @default.
• W4308381568 hasAuthorship W4308381568A5026438002 @default.
• W4308381568 hasAuthorship W4308381568A5048924826 @default.
• W4308381568 hasAuthorship W4308381568A5053055306 @default.
• W4308381568 hasAuthorship W4308381568A5055944597 @default.
• W4308381568 hasAuthorship W4308381568A5068416680 @default.
• W4308381568 hasAuthorship W4308381568A5069069870 @default.
• W4308381568 hasAuthorship W4308381568A5069777765 @default.
• W4308381568 hasAuthorship W4308381568A5071560112 @default.
• W4308381568 hasAuthorship W4308381568A5077439508 @default.
• W4308381568 hasAuthorship W4308381568A5087754052 @default.
• W4308381568 hasAuthorship W4308381568A5087792780 @default.
• W4308381568 hasBestOaLocation W43083815681 @default.
• W4308381568 hasConcept C153911025 @default.
• W4308381568 hasConcept C203014093 @default.
• W4308381568 hasConcept C2776090121 @default.
• W4308381568 hasConcept C2776107976 @default.
• W4308381568 hasConcept C2777701055 @default.
• W4308381568 hasConcept C2781101188 @default.
• W4308381568 hasConcept C502942594 @default.
• W4308381568 hasConcept C553184892 @default.
• W4308381568 hasConcept C86803240 @default.
• W4308381568 hasConcept C8891405 @default.
• W4308381568 hasConceptScore W4308381568C153911025 @default.
• W4308381568 hasConceptScore W4308381568C203014093 @default.
• W4308381568 hasConceptScore W4308381568C2776090121 @default.
• W4308381568 hasConceptScore W4308381568C2776107976 @default.
• W4308381568 hasConceptScore W4308381568C2777701055 @default.
• W4308381568 hasConceptScore W4308381568C2781101188 @default.
• W4308381568 hasConceptScore W4308381568C502942594 @default.
• W4308381568 hasConceptScore W4308381568C553184892 @default.
• W4308381568 hasConceptScore W4308381568C86803240 @default.
• W4308381568 hasConceptScore W4308381568C8891405 @default.
• W4308381568 hasLocation W43083815681 @default.
• W4308381568 hasOpenAccess W4308381568 @default.
• W4308381568 hasPrimaryLocation W43083815681 @default.
• W4308381568 hasRelatedWork W3025154575 @default.
• W4308381568 hasRelatedWork W3028822667 @default.
• W4308381568 hasRelatedWork W3108853735 @default.
• W4308381568 hasRelatedWork W3125366473 @default.
• W4308381568 hasRelatedWork W4224222365 @default.
• W4308381568 hasRelatedWork W4285024394 @default.
• W4308381568 hasRelatedWork W4286629873 @default.
• W4308381568 hasRelatedWork W4304979265 @default.
• W4308381568 hasRelatedWork W4312075079 @default.
• W4308381568 hasRelatedWork W4362003594 @default.
• W4308381568 isParatext "false" @default.
• W4308381568 isRetracted "false" @default.
• W4308381568 workType "article" @default.